This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Death Rates After Surgery and After Surgery Followed by Sodium Iodide I 131

Vijay M. Varma, MD; William H. Beierwaltes, MD; Mohammed M. Nofal, MD; Ronald H. Nishiyama, MD; Jeanne E. Copp, MPH

JAMA. 1970;214(8):1437-1442.

Abstract
A total of 263 patients with histopathologically proved, well-differentiated papillary and follicular thyroid carcinoma were treated with sodium iodide I 131 after surgery. A 100% follow-up was achieved with a mean of 6.3 years, and an observation period of 0 to 20 years. The death rate in these patients was compared with the death rate in 50 patients with papillary and follicular carcinoma of the thyroid treated surgically before introduction of sodium iodide I 131 (control group), and followed for a mean of 6.7 years (0 to 20 years). These groups were matched in sex, but not in age distribution. In patients 40 years of age and older, the group treated with sodium iodide 1131 had a significantly lower death rate than the surgery-only group (P<0.005). There was no significant difference in death rate between patients treated with sodium iodide 1131 and control patients 39 years of age and under.

Author Affiliations
From the departments of internal medicine (nuclear medicine) and pathology, University of Michigan Medical Center, Ann Arbor. Dr. Varma is now with the National Naval Medical Center, Bethesda, Md. Dr. Nofal is now with the University of Alexandria, Alexandria, Egypt.

Footnotes
Read before the Society of Nuclear Medicine, New Orleans, June 25, 1969.

Reprint requests to 1405 E Ann St, Ann Arbor, Mich 48104 (Dr. Beierwaltes).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer
Sawka et al.
J. Clin. Endocrinol. Metab. 2004;89:3668-3676.
ABSTRACT | FULL TEXT  

Rapid Rise in Serum Thyrotropin Concentrations after Thyroidectomy or Withdrawal of Suppressive Thyroxine Therapy in Preparation for Radioactive Iodine Administration to Patients with Differentiated Thyroid Cancer
Serhal et al.
J. Clin. Endocrinol. Metab. 2004;89:3285-3289.
ABSTRACT | FULL TEXT  

Treatment of Thyroid Carcinoma: Emphasis on High-Dose 131I Outpatient Therapy
Parthasarathy and Crawford
J. Nucl. Med. Technol. 2002;30:165-171.
ABSTRACT | FULL TEXT  

Recombinant Human Thyrotropin for the Diagnosis and Treatment of a Highly Functional Metastatic Struma Ovarii
Rotman-Pikielny et al.
J. Clin. Endocrinol. Metab. 2000;85:237-244.
ABSTRACT | FULL TEXT  

Thyroid Cancer: A Lethal Endocrine Neoplasm
Robbins et al.
ANN INTERN MED 1991;115:133-147.
ABSTRACT  

The Surgical Treatment of Thyroid Cancer: The Primary Disease
Ward
Arch Otolaryngol Head Neck Surg 1986;112:1204-1206.
ABSTRACT  

Thyroid Suppression and Medical Ablation for Differentiated Thyroid Cancer
Dunn
Arch Otolaryngol Head Neck Surg 1986;112:1207-1209.
ABSTRACT  

Comparison of 30- and 50-mCi Doses of Iodine-131 for Thyroid Ablation
DEGROOT and REILLY
ANN INTERN MED 1982;96:51-53.
ABSTRACT  

Natural History of Radiation-Associated Thyroid Cancer
Roudebush et al.
Arch Intern Med 1978;138:1631-1634.
ABSTRACT  

Carcinoma of the Thyroid
DeCosse et al.
Arch Surg 1975;110:783-789.
ABSTRACT  

Differentiated Thyroid Carcinomas: Treatment of Distant Metastases
Harness et al.
Arch Surg 1974;108:410-419.
ABSTRACT